1. Home
  2. PGEN vs SGHT Comparison

PGEN vs SGHT Comparison

Compare PGEN & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • SGHT
  • Stock Information
  • Founded
  • PGEN 1998
  • SGHT 2011
  • Country
  • PGEN United States
  • SGHT United States
  • Employees
  • PGEN N/A
  • SGHT N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • SGHT Medical Specialities
  • Sector
  • PGEN Health Care
  • SGHT Health Care
  • Exchange
  • PGEN Nasdaq
  • SGHT Nasdaq
  • Market Cap
  • PGEN 292.6M
  • SGHT 304.4M
  • IPO Year
  • PGEN N/A
  • SGHT 2021
  • Fundamental
  • Price
  • PGEN $0.80
  • SGHT $3.99
  • Analyst Decision
  • PGEN Buy
  • SGHT Buy
  • Analyst Count
  • PGEN 5
  • SGHT 7
  • Target Price
  • PGEN $7.00
  • SGHT $6.58
  • AVG Volume (30 Days)
  • PGEN 930.1K
  • SGHT 227.7K
  • Earning Date
  • PGEN 11-14-2024
  • SGHT 11-07-2024
  • Dividend Yield
  • PGEN N/A
  • SGHT N/A
  • EPS Growth
  • PGEN N/A
  • SGHT N/A
  • EPS
  • PGEN N/A
  • SGHT N/A
  • Revenue
  • PGEN $3,963,000.00
  • SGHT $79,543,000.00
  • Revenue This Year
  • PGEN N/A
  • SGHT $2.18
  • Revenue Next Year
  • PGEN $426.76
  • SGHT $8.14
  • P/E Ratio
  • PGEN N/A
  • SGHT N/A
  • Revenue Growth
  • PGEN N/A
  • SGHT N/A
  • 52 Week Low
  • PGEN $0.76
  • SGHT $2.71
  • 52 Week High
  • PGEN $1.93
  • SGHT $8.45
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 42.83
  • SGHT 43.04
  • Support Level
  • PGEN $0.76
  • SGHT $3.65
  • Resistance Level
  • PGEN $0.97
  • SGHT $4.11
  • Average True Range (ATR)
  • PGEN 0.06
  • SGHT 0.19
  • MACD
  • PGEN -0.01
  • SGHT 0.07
  • Stochastic Oscillator
  • PGEN 20.52
  • SGHT 42.50

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: